Masimo (NASDAQ:MASI) Releases FY 2021 After-Hours Earnings Guidance

Share on StockTwits

Masimo (NASDAQ:MASI) issued an update on its FY 2021
After-Hours earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.80-3.80 for the period, compared to the Thomson Reuters consensus estimate of $3.82. The company issued revenue guidance of $1.2-1.2 billion, compared to the consensus revenue estimate of $1.17 billion.Masimo also updated its FY 2020
After-Hours guidance to 3.46 EPS.

Masimo stock traded down $1.84 during mid-day trading on Wednesday, reaching $276.27. 217,304 shares of the company were exchanged, compared to its average volume of 247,213. Masimo has a 12 month low of $143.90 and a 12 month high of $284.86. The firm has a market cap of $15.21 billion, a PE ratio of 72.43, a PEG ratio of 3.90 and a beta of 0.87. The company has a fifty day simple moving average of $265.65 and a 200-day simple moving average of $238.63.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Saturday, October 31st. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.18. The business had revenue of $278.11 million during the quarter, compared to analysts’ expectations of $275.00 million. Masimo had a net margin of 20.30% and a return on equity of 15.75%. As a group, research analysts expect that Masimo will post 3.46 EPS for the current year.

MASI has been the subject of a number of recent research reports. Piper Sandler upped their target price on Masimo from $250.00 to $280.00 and gave the stock an overweight rating in a report on Wednesday, October 28th. BidaskClub raised Masimo from a buy rating to a strong-buy rating in a research note on Friday, November 6th. Zacks Investment Research downgraded shares of Masimo from a buy rating to a hold rating and set a $258.00 target price on the stock. in a research report on Thursday, October 8th. Raymond James upped their price target on shares of Masimo from $250.00 to $275.00 and gave the company an outperform rating in a research report on Wednesday, October 28th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Masimo in a research note on Tuesday, October 6th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $256.43.

In related news, CFO Micah W. Young sold 10,000 shares of the business’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $239.00, for a total transaction of $2,390,000.00. Following the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $2,390,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joe E. Kiani sold 47,508 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $250.47, for a total value of $11,899,328.76. Following the sale, the chief executive officer now directly owns 206,749 shares of the company’s stock, valued at $51,784,422.03. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 181,781 shares of company stock worth $47,567,263. 11.50% of the stock is owned by corporate insiders.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: Gap Down Stocks

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.